GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States

Completed

Conditions: Influenza

Interventions: Other: Data collection

First Posted Date: 2013-12-24

Last Posted Date: 2017-01-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02019732

Locations: 🇺🇸
GSK Investigational Site, Bethesda, Maryland, United States

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Not Applicable

Completed

Conditions: Pertussis
Pertussis Vaccines

Interventions: Procedure: Blood sampling
Other: Data collection

First Posted Date: 2013-12-18

Last Posted Date: 2019-11-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2000

Registration Number: NCT02014519

Locations: 🇭🇺
GSK Investigational Site, Zirc, Hungary

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Umeclidinium 62.5 mcg
Device: Vilanterol 25 mcg
Device: Umeclidinium/Vilanterol 62.5/25 mcg

First Posted Date: 2013-12-18

Last Posted Date: 2018-02-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 207

Registration Number: NCT02014480

Locations: 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine

Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: GSK2878175
Drug: Placebo

First Posted Date: 2013-12-18

Last Posted Date: 2018-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT02014571

Locations: 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico

Denosumab China Phase III Study

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Placebo
Drug: Denosumab
Dietary Supplement: Elemental Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2013-12-18

Last Posted Date: 2016-10-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 486

Registration Number: NCT02014467

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

A Methodology Study to Assess Muscle Damage After Eccentric Exercise

Phase 1

Completed

Conditions: Tendon Injuries

Interventions: Other: Eccentric exercise

First Posted Date: 2013-12-18

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT02014662

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK2256294

First Posted Date: 2013-12-10

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02006537

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil (GW615775, Test formulation)
Drug: Candesartan cilexetil (Reference treatment)

First Posted Date: 2013-12-10

Last Posted Date: 2018-03-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT02006602

Locations: 🇮🇳
GSK Investigational Site, Hyderabad, India

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil (GW615775, Test formulation)
Drug: Candesartan cilexetil (Reference treatment)

First Posted Date: 2013-12-10

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT02006589

Locations: 🇮🇳
GSK Investigational Site, Hyderabad, India

Darapladib China PK

Phase 1

Completed

Conditions: Atherosclerosis

Interventions: Drug: darapladib 160mg

First Posted Date: 2013-12-04

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02000804

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy